Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page's platform revision was updated from v3.6.4 to v3.6.5, indicating a maintenance release of the ClinicalTrials.gov interface. This reflects an underlying software update rather than a change to study information.
    Difference
    0.0%
    Check dated 2026-08-09T10:56:33.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The revision label was updated to v3.6.4, indicating a new build of the page. This likely reflects maintenance or bug fixes rather than changes to the study information.
    Difference
    0.0%
    Check dated 2026-07-25T23:31:00.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    38 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.2 to v3.6.3, reflecting a new build of the page.
    Difference
    0.0%
    Check dated 2026-07-04T13:25:56.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page's revision version was updated from v3.6.0 to v3.6.2, signaling a subsequent update to the page's content or presentation.
    Difference
    0.0%
    Check dated 2026-06-27T07:38:12.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page now indicates no further participant recruitment and introduces new user-help sections for reading the study record and joining, along with a revision label; a formatting change to the Intervention/Treatment heading is also applied.
    Difference
    0.4%
    Check dated 2026-06-13T04:32:55.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.4 to v3.5.5, indicating a new version of the page content. This appears to be a metadata/software update that does not change the study details, eligibility, or results.
    Difference
    0.0%
    Check dated 2026-06-05T22:02:21.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.